Related: Why are so few patients taking the new drugs for sickle cell?
Next year, two curative gene therapies could be approved for sickle cell disease. Yet drugmakers are pouring billions into developing new and more conventional drugs for the disease, even if they are likely to be far less transformative for individual patients.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
